Quest Diagnostics Inc
NYSE:DGX

Watchlist Manager
Quest Diagnostics Inc Logo
Quest Diagnostics Inc
NYSE:DGX
Watchlist
Price: 184.18 USD 0.86% Market Closed
Market Cap: 20.5B USD

Intrinsic Value

The intrinsic value of one DGX stock under the Base Case scenario is 190.48 USD. Compared to the current market price of 184.18 USD, Quest Diagnostics Inc is Undervalued by 3%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DGX Intrinsic Value
190.48 USD
Undervaluation 3%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Quest Diagnostics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about DGX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is DGX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Quest Diagnostics Inc.

Explain Valuation
Compare DGX to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Quest Diagnostics faces mounting pressure on reimbursement rates from government programs and commercial insurers, which could significantly compress margins and limit revenue growth over the long term.

Increasing competition from independent labs, hospital-based labs, and growing direct-to-consumer testing services threatens Quest Diagnostics’ market share, particularly as smaller, more specialized competitors continue to emerge.

The post-pandemic decline in COVID-19 testing volumes exposes Quest Diagnostics to unpredictable swings in overall testing demand, while its sizable compliance and regulatory costs may hamper operational flexibility in periods of reduced test volumes.

Bull Theses

Quest Diagnostics’ extensive national lab network and established payer relationships position it to leverage scale and offer competitively priced testing, helping defend market share and solidify top-line growth.

The company’s strategic shift toward higher-margin advanced diagnostic services, including genetic and molecular testing, could boost profitability and drive incremental revenue over the long term.

Quest Diagnostics’ strong balance sheet and track record of targeted acquisitions support ongoing expansion into specialized testing niches and new healthcare partnerships, reinforcing its leadership in the diagnostic space.

Show More Less
How do you feel about DGX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Quest Diagnostics Inc

Current Assets 2.4B
Cash & Short-Term Investments 432m
Receivables 1.5B
Other Current Assets 519m
Non-Current Assets 13.8B
Long-Term Investments 137m
PP&E 2.8B
Intangibles 10.6B
Other Non-Current Assets 296m
Current Liabilities 2.1B
Accounts Payable 1.5B
Accrued Liabilities 173m
Other Current Liabilities 504m
Non-Current Liabilities 6.8B
Long-Term Debt 5.2B
Other Non-Current Liabilities 1.6B
Efficiency

Free Cash Flow Analysis
Quest Diagnostics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Quest Diagnostics Inc

Revenue
10.9B USD
Cost of Revenue
-7.2B USD
Gross Profit
3.6B USD
Operating Expenses
-2B USD
Operating Income
1.6B USD
Other Expenses
-633m USD
Net Income
963m USD
Fundamental Scores

DGX Profitability Score
Profitability Due Diligence

Quest Diagnostics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Positive 3Y Average ROE
Healthy Gross Margin
Sustainable 3Y Average Gross Margin
Positive ROE
50/100
Profitability
Score

Quest Diagnostics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

DGX Solvency Score
Solvency Due Diligence

Quest Diagnostics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
46/100
Solvency
Score

Quest Diagnostics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DGX Price Targets Summary
Quest Diagnostics Inc

Wall Street analysts forecast DGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DGX is 200.59 USD with a low forecast of 170.87 USD and a high forecast of 225.75 USD.

Lowest
Price Target
170.87 USD
7% Downside
Average
Price Target
200.59 USD
9% Upside
Highest
Price Target
225.75 USD
23% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Dec 5, 2025
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Shareholder Yield

Current shareholder yield for DGX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

DGX Insider Trading
Buy and sell transactions by insiders

DGX News

Other Videos
What is the Intrinsic Value of one DGX stock?

The intrinsic value of one DGX stock under the Base Case scenario is 190.48 USD.

Is DGX stock undervalued or overvalued?

Compared to the current market price of 184.18 USD, Quest Diagnostics Inc is Undervalued by 3%.

Back to Top